With multiple pathways and stakeholders involved, there needs to be an arbiter who decides what is the highest quality and highest value care in oncology, said Lucy Langer, MD, MSHS, national medical director, oncology and genomics, UnitedHealthcare.
With multiple pathways and stakeholders involved, there needs to be an arbiter who decides what is the highest quality and highest value care in oncology, said Lucy Langer, MD, MSHS, national medical director, oncology and genomics, UnitedHealthcare.
Transcript
When looking at value-based care, who should decide what value really is?
One of the things I'm going to talk about this evening is drug pathways. There are many drug pathways out there. There are provider pathways, there are payer pathways, and then there's the NCCN [National Comprehensive Cancer Network] preferred pathways. And they're all different.
They do have areas of overlap, but they're all different. And when 3 major players in the health system and in oncology can't agree on pathways, at some point, you have to decide who's the ultimate arbiter of the pathways and decide: are we going to go with that group's pathways to help promote highest quality, highest value care? We're going to talk about that a little bit. I think it raises more questions than answers.
My personal philosophy is that the practicing oncologist should be the one who determines what's best for the patient. For groups like Rocky Mountain Cancer Centers, who are hosting tonight's event, I have no qualms whatsoever about them being the arbiter of what's best. But in my role at UnitedHealthcare—having been in this seat now for a year—I can say the variability in quality and integrity in selection of regimens is vast across the United States.
While here in Colorado, we may not have so much of an issue, from a national perspective, we're trying to thread that needle and figure out how do we best promote highest quality care for value contracting.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
The Joint Commission is launching the Rural Health Clinic Accreditation Program to standardize staff training and patient care practices at rural health clinics nationwide; the American Cancer Society recently launched the largest-ever study of cancer risk and outcomes in Black women; the HHS COVID-19 vaccination campaign saved $732 billion by preventing illness and related costs.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen